Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis

CONCLUSIONS: This study propose that JAK-inhibitors perhaps provide advantageous effects on Covid-19 outcomes. JAK-inhibitors may be given during 1 - 2 weeks of disease to optimize its beneficial effects in halting the exaggerated immune response.PMID:34538216 | DOI:10.1080/14787210.2021.1982695

Source: Expert Review of Anti-Infective Therapy - September 20, 2021 Category: Infectious Diseases Authors: Ronal Yosua Limen Rudyanto Sedono Adhrie Sugiarto Timotius Ivan Hariyanto Source Type: research